Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;35:1002-1008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sjögren, L. S.
Right arrow Articles by Jern, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sjögren, L. S.
Right arrow Articles by Jern, S.
Related Collections
Right arrow Cell biology/structural biology
Right arrow Gene expression
Right arrow Gene regulation
Right arrow Hypertension - basic studies
Right arrow Fibrinolysis
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2000;35:1002.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Elevated Intraluminal Pressure Inhibits Vascular Tissue Plasminogen Activator Secretion and Downregulates Its Gene Expression

Lena Selin Sjögren; Roya Doroudi; Li-ming Gan; Lennart Jungersten; Thórdís Hrafnkelsdóttir; Sverker Jern

From the Clinical Experimental Research Laboratory, Heart and Lung Institute, Sahlgrenska University Hospital/Östra, Göteborg University, Göteborg, Sweden.

Correspondence to Dr Sverker Jern, Clinical Experimental Research Laboratory, Sahlgrenska University Hospital/Östra, SE 416 85 Göteborg, Sweden. E-mail sverker.jern{at}hjl.gu.se

Abstract—We recently discovered that patients with essential hypertension have a markedly impaired capacity for stimulated release of tissue plasminogen activator (tPA) from vascular endothelium. This defect may reduce the chance of timely spontaneous thrombolysis in case of an atherothrombotic event. We now investigated whether increased intraluminal pressure as such may depress vascular tPA release or downregulate its gene expression. Segments of human umbilical veins were studied in a new computerized vascular perfusion model under steady laminar flow conditions for 3 or 6 hours. Paired segments were perfused at high or physiological intraluminal pressure (40 versus 20 mm Hg) under identical shear stress (10 dyne/cm2). Quantitative immunohistochemical evaluation of cellular tPA immunoreactivity was performed on paraffin-embedded 5-µm vascular sections. tPA mRNA in endothelial cells was quantified with reverse transcription real-time TaqMan polymerase chain reaction with GAPDH as endogenous control. Secretion of tPA into perfusion medium was evaluated with SDS-PAGE and Western blotting, followed by densitometric quantification. High-pressure perfusion downregulated tPA gene expression with a 38% decrease in tPA mRNA levels (P=0.01) compared with vessels perfused under normal intraluminal pressure. tPA release into the perfusion medium was markedly suppressed by high pressure (P<0.01 ANOVA). The intracellular storage pool of tPA was reduced after 6 but not 3 hours. Thus, elevated intraluminal pressure downregulates tPA gene and protein expression and inhibits its release from the endothelium independently of shear stress. The defective capacity for stimulated tPA release that we demonstrated in patients with essential hypertension might thus be an effect of the elevated intraluminal pressure per se.


Key Words: endothelium • plasminogen activators • fibrinolysis • gene expression




This article has been cited by other articles:


Home page
StrokeHome page
G. Tsivgoulis, M. Saqqur, V. K. Sharma, A. Y. Lao, M. D. Hill, A. V. Alexandrov, and for the CLOTBUST Investigators
Association of Pretreatment Blood Pressure With Tissue Plasminogen Activator-Induced Arterial Recanalization in Acute Ischemic Stroke
Stroke, March 1, 2007; 38(3): 961 - 966.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. Ridderstrale, E. Ulfhammer, S. Jern, and T. Hrafnkelsdottir
Impaired Capacity for Stimulated Fibrinolysis in Primary Hypertension Is Restored by Antihypertensive Therapy
Hypertension, April 1, 2006; 47(4): 686 - 691.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. J. Oliver, D. J. Webb, and D. E. Newby
Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans
Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2470 - 2479.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. K. Bidani and K. A. Griffin
Pathophysiology of Hypertensive Renal Damage: Implications for Therapy
Hypertension, November 1, 2004; 44(5): 595 - 601.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Hrafnkelsdottir, P. Ottosson, T. Gudnason, O. Samuelsson, and S. Jern
Impaired Endothelial Release of Tissue-Type Plasminogen Activator in Patients With Chronic Kidney Disease and Hypertension
Hypertension, September 1, 2004; 44(3): 300 - 304.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Uhlig
Mechanotransduction in the Lung: Ventilation-induced lung injury and mechanotransduction: stretching it too far?
Am J Physiol Lung Cell Mol Physiol, May 1, 2002; 282(5): L892 - L896.
[Abstract] [Full Text] [PDF]